Ask sales for the lot-numbered COA matched to the offered or supplied batch; it records the tests actually completed, their specifications, and the reported results.
Review the matching batch COA for the analytical scope and results recorded for that lot.
Matching batch COA available.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Tirzepatide, Semaglutide, Retatrutide, Cagrilintide and related GLP-1 / GIP / GCG receptor agonists for metabolic and weight-management research.
GIP / GLP-1 dual receptor agonist
GIP / GLP-1 / glucagon tri-agonist
GLP-1 receptor agonist
Long-acting amylin analog
Nicotinamide adenine dinucleotide
Reference-code fill; Retatrutide identity verified per batch COA · 30 mg
Reference-code fill; Retatrutide identity verified per batch COA · 5 mg
Reference-code fill; Semaglutide identity verified per batch COA · 30 mg
Reference-code fill; Tirzepatide identity verified per batch COA · 10 mg
Reference-code fill; Tirzepatide identity verified per batch COA · 30 mg
Reference-code fill; Tirzepatide identity verified per batch COA · 60 mg
GLP-1 receptor agonist (long-acting)
GLP-1 / glucagon dual receptor agonist (IBI362 / LY3305677)
GLP-1 / glucagon dual receptor agonist (BI 456906)
NNMT inhibitor (5-Amino-1-methylquinolinium iodide)
AMPK pathway activator · exercise mimetic research compound
Fatty-acid-transport nutrient
Pan-ERR agonist · exercise mimetic compound
19-mer
Prohibitin-targeting adipose vascular peptide
Long-acting GLP-1 Fc-fusion protein · incretin research reference
Applications & buyer fit
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Buyer types across this category
Documentation available for this class
Sold as a bulk active for research and for compounding-pharmacy formulation in jurisdictions where local regulations permit. Not a finished dosage form and not labeled for direct human administration as shipped. The GLP-1 class is on active regulatory watchlists in several major markets, buyers are responsible for verifying current scheduling and compounding eligibility for the destination at the time of dispense.